Safety and efficacy of the MDR inhibitor incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 4, 2003, Pages 297-305

  Rago, Randall P ^a   Einstein Jr , Albert ^a   Lush, Richard ^a   Beer, Tomasz M ^b   Ko, Yoo Joung ^c   Henner, W David ^b   Bubley, Glenn ^c   Merica, Elizabeth A ^d   Garg, Varun ^d   Ette, Ene ^d   Harding, Matthew W ^d   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

HRPC; Mitoxantrone; Multidrug resistance; VX 710

Indexed keywords

BIRICODAR; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR; TESTOSTERONE;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATAXIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; VERTIGO; VOMITING;

EID: 0038239592     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0573-4     Document Type: Article

References (43)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361
2. Batra S, Karlsson R, Witt L (1996) Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 68:644
3. Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J (2000) Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 5:118
4. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295
5. Bradshaw DM, Arceci RJ (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16:3674
6. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD (2002) Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 8:383-393
7. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461
8. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug effiux pump, in human hematopoietic stem cells. Cell 66:85
9. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902
10. Culine S, Droz JP (2000) Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 11:1523
11. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729
12. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365
13. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070
14. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237
15. Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW (1997) Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141
16. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125
17. Hipfner DR, Deeley RG, Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461:359
18. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156
19. Izbicka E, Dalton WS, Troyer D, Von Hoff DD (1998) Expression of two multidrug resistance genes in human prostatic carcinomas. J Natl Cancer Inst 90:166
20. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506
21. Kawai K, Sakurai M, Sakai T, Misaki M, Kusano I, Shiraishi T, Yatani R (2000) Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 150:147
22. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H (2001) Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44
23. Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319
24. Oh WK (2000) Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 88:3015
25. Oh WK, Kantoff PW (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160:1220
26. Oh WK, Kantoff PW (1999) Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 17:3664
27. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ (2001) Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130
28. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958
29. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16:2964
30. Schummer B, Siegsmund M, Steidler A, Toktomambetova L, Kohrmann KU, Alken P (1999) Expression of the gene for the multidrug resistance-associated protein in human prostate tissue. Urol Res 27:164
31. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM (1994) Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151:485
32. Siegsmund MJ, Kreukler C, Steidler A, Nebe T, Kohrmann KU, Alken P (1997) Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res 25:35
33. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1
34. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664
35. Sonneveld P (2000) Multidrug resistance in haematological malignancies. J Intern Med 247:521
36. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD (1994) P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 86:688
37. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN (1998) The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393
38. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756
39. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD (2002) Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8:670-678
40. Van Brussel JP, Van Steenbrugge GJ, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schroder FH, Mickisch GH (2001) Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 165:130
41. Wiseman LR, Spencer CM (1997) Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 10:473
42. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K (1999) BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer 80:1190
43. Yang CP, Shen HJ, Horwitz SB (1994) Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 86:723